BioOra and Octane Biotech Sign LOI for Cocoon® Platform Expansion in Cell Therapy
BioOra Limited and Octane Biotech Inc. have signed a Letter of Intent to enhance CAR-T cell therapy manufacturing using the Cocoon® platform. This collaboration aims to expand production capacity in Australia and other international markets, improving patient access to advanced therapies.
Theia Market Signal Identification - AI Assisted
BioOra and Octane Biotech have entered into a Letter of Intent to collaborate on advanced cell therapy manufacturing using the Cocoon® platform. The partnership will enhance BioOra's CAR-T therapy production, initially in Australia, and extend to other markets.
BioOra is building a new manufacturing facility in Christchurch, New Zealand, to support this initiative. The collaboration will focus on scaling operations, improving manufacturing efficiency, and expanding access to CAR-T therapies. By integrating automation with manufacturing processes, this partnership could significantly change the landscape for cell therapy delivery.
Comments